Index Entries

Yuyang Lei, Jiao Zhang, Cara R. Schiavon, Ming He, Lili Chen, Hui Shen, Yichi Zhang, Qian Yin, Yoshitake Cho, Leonardo Andrade, Gerald S. Shadel, Mark Hepokoski, Ting Lei, Hongliang Wang, Jin Zhang, Jason X.-J. Yuan, Atul Malhotra, Uri Manor, Shengpeng Wang, Zu-Yi Yuan, and John Y-J. Shyy
March 31, 2021
Circulation Research
Salk Institute

Includes images of “[r]epresentative images of vascular endothelial control cells (left) and cells treated with the SARS-CoV-2 Spike protein (right) [which] show that the spike protein causes increased mitochondrial fragmentation in vascular cells.” BBB “SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection relies on the binding of S protein (Spike glycoprotein) to ACE (angiotensin-converting enzyme) 2 in the host cells. Vascular endothelium can be infected by SARS-CoV-2, which triggers mitochondrial reactive oxygen species production and glycolytic shift. Paradoxically, ACE2 is protective in the cardiovascular system, and SARS-CoV-1 S protein promotes lung injury by decreasing the level of ACE2 in the infected lungs. In the current study, we show that S protein alone can damage vascular endothelial cells (ECs) by downregulating ACE2 and consequently inhibiting mitochondrial function.”

document
adverse events,COVID-19,vaccine systemic and virological concerns,mRNA,SARS-CoV-2 spike protein,vaccines